Angiotensin II and the glomerulus: Focus on diabetic kidney disease

Current Hypertension Reports

Volumn 5, Issue 2, 2003, Pages 172-180

  Scholey, James W ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IRBESARTAN; LOSARTAN; PLACEBO; VALSARTAN; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR;

BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DISEASE COURSE; EXTRACELLULAR SPACE; GLOMERULUS; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANGIOTENSIN II; ANIMALS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; HUMANS; KIDNEY GLOMERULUS; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 0038351064     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-003-0075-0     Document Type: Review

References (65)

1. Burns KD, Homma T, Harris RC: The intrarenal renin-angiotensin system. Semin Nephrol 1993, 13:13-30.
2. Burns KD: Angiotensin II and its receptors in the diabetic kidney. Am J Kidney Dis 2000, 36:449-467.
3. Zatz R, Dunn BR, Meyer TW, et al.: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986, 77:1925-1930.
4. Price DA, Porter LE, Gordon M, et al.: The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol 1999, 10:2382-2391.
5. Anderson S, Jung FF, Inglefinger JR: Renal renin-angiotensin system in diabetes: Functional, immunohistochemical, and molecular biological correlations. Am J Physiol 1993, 265:F477-F486.
6. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000, 355:253-259.
7. UKPDS 39: U.K. Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes. BMJ 1998, 317:713-720.
8. The ACE Inhibitors in Diabetic Nephropathy Trialist Group: Should all type 1 diabetic patients with microalbuminuria receive ACE inhibitor treatment? A meta regression analysis. Ann Intern Med 2001, 134:370-379.
9. Cooper ME: Renal protection and angiotensin converting enzyme inhibition in microalbuminuric type I and II diabetic patients. J Hypertens 1996, 14:S11-S14.
10. Maschio G, Alberti D, Janin C, et al.: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996, 334:939-945.
11. The GISEN Group: Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997, 349:1857-1863.
12. Miller JA: Impact of hyperglycemia on the renin-angiotensin system in early human type I diabetes mellitus. J Am Soc Nephrol 1999, 10:1778-1785.
13. Zimplemann J, Kumar D, Levine DZ, et al.: Early diabetes mellitus stimulates tubule renin mRNA expression in the rat. Kidney Int 2000, 58:2320-2330.
14. Correa-Rotter R, Hostetter TH, Rosenberg ME: Renin and angiotensinogen gene expression in experimental diabetes mellitus. Kidney Int 1992, 41:796-804.
15. Zhang S-L, Filep JG, Hohman TC, et al.: Molecular mechanism of glucose action on angiotensinogen gene expression in rat proximal tubular cells. Kidney Int 1999, 55:454-464.
16. Brown L, Wall D, Marchant C, Sernia C: Tissue-specific changes in angiotensin II receptors in streptozotocin-diabetic rats. J Endocrinol 1997, 154:355-362.
17. Kalinyak JE, Sechi LA, Griffin CA, et al.: The renin-angiotensin system in streptozocin-induced diabetes mellitus in the rat. J Am Soc Nephrol 1993, 4:1337-1345.
18. Wang T-T, Wu X-H, Zhang S-L, Chan JSD: Effect of glucose on the expression of the angiotensinogen gene in opossum kidney cells. Kidney Int 1998, 53:312-319.
19. Remuzzi G, Bertani T: Pathophysiology of progressive nephropathies. N Engl J Med 1998, 339:1448-1456.
20. El Nahas AM: Progression of chronic renal failure. In Comprenhensive Clinical Nephrology. Edited by Johnson RJ, Feehally J. New York: Mosby Harcourt; 2000:6690-6710.
21. Breyer JA, Bain RP, Evans JK, et al.: Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. The Collaborative Study Group. Kidney Int 1996, 50:1651-1658.
22. Peterson JC, Adler S, Burkart JM, et al.: Blood pressure control, proteinuria, and the progression of renal disease. Ann Intern Med 1995, 123:754-762.
23. Burton C, Harris KP: The role of proteinuria in the progression of chronic renal failure. Am J Kidney Dis 1996, 27:765-775.
24. Abbate M, Zoja C, Corna D, et al.: Progressive nephropathies: overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation. J Am Soc Nephrol 1998, 9:1213-1224.
25. Ruggenenti F, Perna A, Gherardi G, et al.: Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis 2000, 35:1155-1165.
26. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group: The effect of angiotensin-converting enzyme on diabetic nephropathy. N Engl J Med 1993, 329:1456-1462.
27. Microalbuminuria Study Group: Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria: the Microalbuminuria Captopril Study Group. Diabetologia 1996, 39:587-593.
28. Viberti G, Mogensen CE, Groop LC, Pauls JF, for the European Microalbuminuria Captopril Study Group: Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA 1994, 271:275-279.
29. Parving H-H, Lehnert H, Brochner-Mortensen J, et al., for the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870-878.
30. Viberti G, Wheeldon NM: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. Circulation 2002, 106:672-678.
31. Lacourciere Y, Belanger A, Godin C, et al.: Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kindey Int 2000, 58:762-769.
32. Brenner BM, Cooper ME, De Zeeuw D, et al., for the RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
33. Lewis EJ, Hunsicker LG, Clarke WR, et al., for the Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860.
34. Remuzzi A, Perico N, Sangalli F, et al.: ACE inhibition and Ang II blockade improve glomerular size-selectivity in IgA nephropathy. Am J Physiol 1999, 276:F457-F466.
35. Deen WM, Bridges CR, Brenner BM, Myers BD: Heteroporous model of glomerular size selectivity: application to normal and nephrotic humans. Am J Physiol 1985, 249:F374-F389.
36. Blantz RC, Konnen KS, Tucker BJ: Angiotensin effects upon the glomerular microcirculation and ultrafiltration coefficient of the rat. J Clin Invest 1976, 57:419-434.
37. Mezzano SA, Ruiz-Ortega M, Egido J: Angiotensin II and renal fibrosis. Hypertension 2001, 38:635-638.
38. Wolf G, Neilson EG: Angiotensin II as a renal growth factor. J Am Soc Nephrol 1993, 3:1531-1540.
39. G, Ziyadeh FN, Zahner G, Stahl RA: Angintensin II is mitogenic for cultured rat glomerular endothelial cells. Hypertension 1997, 27:897-905.
40. Wolf G, Haberstroh U, Neilson EG: Angintensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells. Am J Pathol 1992, 140:95-107.
41. Singh R, Alavi N, Singh AK, Leehey DJ: Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabetes 1999, 48:2066-2073.
42. Ray PE, Bruggeman LA, Horikoshi S, et al.: Angiotensin II stimulates human fetal mesangial cell proliferation and fibronectin biosynthesis by binding to AT1 receptors. Kidney Int 1994, 45:177-184.
43. Vaughan DE, Lazos SA, Tong K: Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells: A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995, 95:995-1001.
44. Nakamura S, Nakamura I, Ma L, et al.: Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney Int 2000, 58:251-259.
45. Wolf G, Killen PD, Neilson EG: Intracellular signalling of transcription and secretion of type IV collagen after angiotensin II-induced cellular hypertrophy in cultured proximal tubular cells. Cell Regul 1991, 2:219-227.
46. Ruiz-Ortega M, Lorenzo O, Suzuki Y, et al.: Proinflammatory actions of angintensin II. Curr Opin Nephrol Hypertens 2001, 10:321-329.
47. Wolf G, Ziyadeh FN, Thaiss F, et al.: Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells: role of the angiotensin type II receptor. J Clin Invest 1997, 100:1047-1058.
48. Ruiz-Ortega M, Lorenzo O, Egido J: Angintensin III increases monocytic chemotactic protein-1 and activates nuclear factor B in cultured mesangial cells and mononuclear cells. Kidney Int 2000, 57:2285-2298.
49. Marrero MB, Schieffer B, Paxton WG, et al.: Direct stimulation of JAK/STAT pathway by the angintensin II AT1 receptor. Nature 1995, 375:247-250.
50. Kagami S, Border WA, Miller DE, Noble NA: Angiotensin II stimulates extracellular matrix protein synthesis through activation of transforming growth factor- synthesis in rat glomerular cells. J Clin Invest 1994, 93:2431-2437.
51. Border WA, Noble NA: Interactions of transforming growth factor-β and angiotensin II in renal fibrosis. Hypertension 1998, 31:181-188.
52. Wolf G, Ziyadeh FN, Stahl RA: Angiotensin II stimulates expression of transforming growth factor beta receptor type II in cultured mouse proximal tubular cells. J Mol Med 1999, 77:556-564.
53. Moriyama T, Fujibayashi M, Fujiwara Y, et al.: Angiotensin II stimulates interleukin-6 release from cultured mouse mesangial cells. J Am Soc Nephrol 1995, 6:95-101.
54. Kato S, Luyckx VA, Ots M, et al.: Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats. Kidney Int 1999, 56:1037-1048.
55. Ziyadeh FN, Hoffman BB, Han DC, et al.: Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A 2000, 97:8015-8020.
56. Ruiz-Ortega M, Egido J: Angiotensin II modulates cell growth-related events and synthesis of matrix proteins in renal interstitial fibroblasts. Kidney Int 1997, 52:1497-1510.
57. Ishidoya S, Morrissey J, McCracken R, et al.: Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. Kidney Int 1995, 47:1285-1294.
58. Agarwal R, Siva S, Dunn SR, Sharma K: Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels. Am J Kidney Dis 2002, 39:486-492.
59. Sharma K, Ziyadeh FN, Alzahabi B, et al.: Increased renal production of transforming growth factor-beta1 in patients with type II diabetes. Diabetes 1997, 46:854-859.
60. Sato H, Iwano M, Akai Y, et al.: Increased excretion of urinary transforming growth factor beta 1 in patients with diabetic nephropathy. Am J Nephrol 1998, 18:490-494.
61. Parving H-H, Osterby R, Ritz E: Diabetic nephropathy. In The Kidney, edn 6. Edited by Brenner BM. Philadelphia: WB Saunders; 2000:1731-1773.
62. Mogensen C: Microalbuminuria predicts clinical proteinuria and early mortality in maturity onset diabetes. N Engl J Med 1984, 310:356-360.
63. Mogensen CE, Keane WF, Bennett PH, et al.: Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995, 346:1080-1084.
64. Nelson RG, Bennett PH, Beck GJ, et al.: Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. N Engl J Med 1996, 335:1636-1642.
65. Shahinfar S, Dickson TZ, Ahmed T, et al.: Losartan in patients with type 2 diabetes mellitus and proteinuria: observations from the RENAAL Study. Kidney Int 2002, 62(Suppl 82):S64-S67.